FDA-cleared profile

syngo.CT Lung CAD

Siemens Medical Solutions, Inc · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.

Clinical role
Second-reader support after the radiologist completes the initial read, with ROI alerting and full professional review of the case.
Images and patients
CT/CTA · Solid pulmonary nodules in the thorax.
Key limitation
Keep in mind: The FDA scope is solid pulmonary nodules at least 3 mm and less than 20 mm in diagnostic chest MDCT, with central or peripheral location and round or irregular contour. The device is second-reader only, the output is evaluated by trained professionals, and the original acquired data are not changed.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Solid pulmonary nodules in the thorax. Input: Thoracic MDCT from Siemens multi-detector CT scanners with four or more detector rows, covering the entire thorax from lung apices to bases; the device is optimized for solid nodules at least 3 mm and less than 20 mm, with cranio-caudal or caudal-cranial scan direction and the table's stated CT input parameters.
  • Who uses it?Intended users: Radiologists and trained professionals evaluating the CAD output.
  • What does the software produce?Output: A list of nodule candidate locations sent to syngo MM Oncology or another visualization/rendering component, which produces output image series with CAD marks superimposed on the input thoracic CT images.
  • What is its most important limitation?Key limitation: The FDA scope is solid pulmonary nodules at least 3 mm and less than 20 mm in diagnostic chest MDCT, with central or peripheral location and round or irregular contour. The device is second-reader only, the output is evaluated by trained professionals, and the original acquired data are not changed.

Clinical takeaway. Clinical role: Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.

Evidence takeaway. Evidence from the reviewed source record: Performance testing found the VC30 standalone sensitivity superior to VC20 and the false-positive rate reduced; true-positive and false-positive marks were reasonably consistent with the predicate in location and extent. The packet states that endpoint definitions and sample size were set in the test protocols but reports no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta results.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive CAD assistance to alert radiologists to potentially overlooked solid pulmonary nodules during chest MDCT review; second-reader use only after the radiologist's initial read.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Second-reader support after the radiologist completes the initial read, with ROI alerting and full professional review of the case.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Thoracic MDCT from Siemens multi-detector CT scanners with four or more detector rows, covering the entire thorax from lung apices to bases; the device is optimized for solid nodules at least 3 mm and less than 20 mm, with cranio-caudal or caudal-cranial scan direction and the table's stated CT input parameters.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
A list of nodule candidate locations sent to syngo MM Oncology or another visualization/rendering component, which produces output image series with CAD marks superimposed on the input thoracic CT images.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Diagnostic chest CT reading workflow.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Radiologists and trained professionals evaluating the CAD output.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The FDA scope is solid pulmonary nodules at least 3 mm and less than 20 mm in diagnostic chest MDCT, with central or peripheral location and round or irregular contour. The device is second-reader only, the output is evaluated by trained professionals, and the original acquired data are not changed.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
Performance testing found the VC30 standalone sensitivity superior to VC20 and the false-positive rate reduced; true-positive and false-positive marks were reasonably consistent with the predicate in location and extent. The packet states that endpoint definitions and sample size were set in the test protocols but reports no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta results.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Performance testing found the VC30 standalone sensitivity superior to VC20 and the false-positive rate reduced; true-positive and false-positive marks were reasonably consistent with the predicate in location and extent. The packet states that endpoint definitions and sample size were set in the test protocols but reports no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta results.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K193216. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Thoracic MDCT from Siemens multi-detector CT scanners with four or more detector rows, covering the entire thorax from lung apices to bases; the device is optimized for solid nodules at least 3 mm and less than 20 mm, with cranio-caudal or caudal-cranial scan direction and the table's stated CT input parameters.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K193216: syngo.CT Lung CAD

  2. Routing

    Source context, not route validation: The algorithm has no own display UI and sends candidate locations to syngo MM Oncology or a visualization/rendering component; syngo MM Oncology runs on syngo.via for CAD-mark display. Specific local PACS or RIS compatibility is not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K193216: syngo.CT Lung CAD

  3. AI processing

    Source context, not route validation: The exact FDA package describes syngo.CT Lung CAD VC30 as having syngo.via as its hosting platform and syngo MM Oncology as its hosting application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Hosting Platform syngo.via syngo.via Hosting Application syngo MM Oncology syngo MM Oncology". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K193216: syngo.CT Lung CAD

  4. Returned objects

    Source context, not route validation: A list of nodule candidate locations sent to syngo MM Oncology or another visualization/rendering component, which produces output image series with CAD marks superimposed on the input thoracic CT images.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K193216: syngo.CT Lung CAD

  5. Viewer/worklist/report

    Unresolved route: A list of nodule candidate locations sent to syngo MM Oncology or another visualization/rendering component, which produces output image series with CAD marks superimposed on the input thoracic CT images.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K193216: syngo.CT Lung CAD

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes syngo.CT Lung CAD VC30 as having syngo.via as its hosting platform and syngo MM Oncology as its hosting application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Hosting Platform syngo.via syngo.via Hosting Application syngo MM Oncology syngo MM Oncology". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The algorithm has no own display UI and sends candidate locations to syngo MM Oncology or a visualization/rendering component; syngo MM Oncology runs on syngo.via for CAD-mark display. Specific local PACS or RIS compatibility is not established.
  • Exact FDA submission
  • Checked 2026-09-09
Training
The 510(k) summary states syngo.CT Lung CAD is utilized only by trained professionals and that the output of the device is evaluated by trained professionals as a second reader.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for syngo.CT Lung CAD; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K193216
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Solid pulmonary nodules in the thorax.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-03-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
17Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K193216 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K193216: syngo.CT Lung CAD

    U.S. Food and Drug Administration - Published 2020-03-09 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. syngo.CT Lung CAD model card (K193216)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: anatomy

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K193216

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K193216 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K254075

Synapse Lung Nodule AI

Fujifilm Corporation

Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.

Modality
CT/CTA
Anatomy
Chest/lungs; pulmonary nodules
Decision
2026-05-27
FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K251769

RevealAI-Lung

Precision Medical Ventures, Inc. Dba Revealdx

Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening

Modality
CT/CTA
Anatomy
Pulmonary nodules in the lungs
Decision
2026-01-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history